Japanese Journal of Cancer and Chemotherapy最新文献

[A Case of Giant Exophytic Gastric GIST Presenting with the Torricelli-Bernoulli Sign during Regorafenib Treatment]. [1例巨大外生性胃间质瘤在瑞非尼治疗期间出现Torricelli-Bernoulli征象]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Kohei Asada, Hiroaki Miyake, Yu Aoki, Keiichi Narita, Fumihiko Kato, Fumiki Toriumi, Takashi Endo, Atsushi Nakazawa, Shigemichi Hirose, Shinsuke Funakoshi

{"title":"[A Case of Giant Exophytic Gastric GIST Presenting with the Torricelli-Bernoulli Sign during Regorafenib Treatment].","authors":"Kohei Asada, Hiroaki Miyake, Yu Aoki, Keiichi Narita, Fumihiko Kato, Fumiki Toriumi, Takashi Endo, Atsushi Nakazawa, Shigemichi Hirose, Shinsuke Funakoshi","doi":"","DOIUrl":"","url":null,"abstract":"Following surgery for rectal cancer and resection of the liver metastases, a giant gastric GIST was detected in an 81-yearold man during follow-up. Imatinib and sunitinib were administered; however, the tumor was refractory. Follow-up CT scans obtained while receiving regorafenib as third-line therapy revealed an increase in tumor size, and the disease was assessed as progressive (PD). At that time, a Torricelli-Bernoulli (T-B) sign was observed, indicating communication between the tumor interior and the gastric lumen. Reports of perforation during regorafenib administration are scarce, and the mechanisms underlying these events have not been fully elucidated. Conventionally, the T-B sign indicates tumor necrosis or perforation associated with a therapeutic response to GIST treatment. However, in this case, it is believed that structural destruction of the gastric wall resulted from tumor enlargement owing to drug resistance, thereby leading to the presence of gas. Therefore, we report this case as this course of events was highly informative to our understanding of the process of GIST perforation.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"583-586"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Overexpression of JMJD6 Drives Immune Evasion via the BRD4-IRF1-PD-L1 Axis and Promotes Malignancy in Gastric Cancer]. [JMJD6过表达通过BRD4-IRF1-PD-L1轴驱动免疫逃避并促进胃癌恶性肿瘤]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Ryo Ishida, Shuhei Komatsu, Hiroshi Arakawa, Takuma Ohashi, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Yusuke Takashima, Hajime Kamiya, Satoshi Hamada, Masateru Yamauchi, Hiroki Shimizu, Tomohiro Arita, Toshiyuki Kosuga, Hirotaka Konishi, Hitoshi Fujiwara, Tomoko Iehara, Hitoshi Tsuda, Atsushi Shiozaki

{"title":"[Overexpression of JMJD6 Drives Immune Evasion via the BRD4-IRF1-PD-L1 Axis and Promotes Malignancy in Gastric Cancer].","authors":"Ryo Ishida, Shuhei Komatsu, Hiroshi Arakawa, Takuma Ohashi, Taisuke Imamura, Jun Kiuchi, Keiji Nishibeppu, Yusuke Takashima, Hajime Kamiya, Satoshi Hamada, Masateru Yamauchi, Hiroki Shimizu, Tomohiro Arita, Toshiyuki Kosuga, Hirotaka Konishi, Hitoshi Fujiwara, Tomoko Iehara, Hitoshi Tsuda, Atsushi Shiozaki","doi":"","DOIUrl":"","url":null,"abstract":"JMJD6, a jumonji C domain-containing protein located in the cancer-amplified region 17q25, has emerged as a putative oncogene in several malignancies. Only a few reports identified its function in gastric cancer (GC). In this study, we investigated the oncogenic and immunosuppressive roles of JMJD6 and its clinical relevance in GC. We analyzed 6 GC cell lines and 174 primary tumors. Overexpression of JMJD6 was frequently detected in GC cell lines (4/6 cell lines, 66.7%) and 69 primary GC specimens. Overexpression of JMJD6 was significantly associated with advanced tumor stage and was an independent poor prognostic factor (p<0.001, hazard ratio 4.15). Knockdown of JMJD6 suppressed GC cell proliferation, migration and invasion in a TP53 mutation-independent manner, and reduced programmed death-ligand 1 (PD-L1) expression via bromodomain-containing protein 4 (BRD4) and interferon regulatory factor 1 (IRF1) down-regulation. Ectopic overexpression of JMJD6 induced PD-L1 expression via BRD4 and IRF1 upregulation in low-PD-L1-expressing cells. In co-culture assays with activated T cells, JMJD6 knockdown enhanced tumor immunogenicity and T cell-mediated cytotoxicity. In primary GC samples, JMJD6 expression correlated positively with PD-L1 expression. These findings suggest that JMJD6 functions as a dual regulator of tumor aggressiveness and immune escape, highlighting its utility as a prognostic factor and a promising therapeutic target in GC.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"560-565"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Post-Transplant Lymphoproliferative Disorder with Suspected Thrombosis Leading to Discontinuation of Daprodustat Following Pharmacist Intervention]. [1例移植后淋巴细胞增生性疾病合并疑似血栓形成，药师干预后停用达普司他]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Takuya Watanabe, Masanobu Uchiyama, Junichi Matsumoto, Yuta Nakashima, Ayaka Shibata, Hideki Kakimoto, Takafumi Nakano, Masaya Adachi, Marie Yoshioka, Risako Fujikawa, Katsunori Iwasaki, Koichi Matsuo

{"title":"[A Case of Post-Transplant Lymphoproliferative Disorder with Suspected Thrombosis Leading to Discontinuation of Daprodustat Following Pharmacist Intervention].","authors":"Takuya Watanabe, Masanobu Uchiyama, Junichi Matsumoto, Yuta Nakashima, Ayaka Shibata, Hideki Kakimoto, Takafumi Nakano, Masaya Adachi, Marie Yoshioka, Risako Fujikawa, Katsunori Iwasaki, Koichi Matsuo","doi":"","DOIUrl":"","url":null,"abstract":"A woman in her 50s was diagnosed with post-transplant lymphoproliferative disorder, diffuse large B-cell lymphoma, and germinal center B-cell-like type based on a lower gastrointestinal tract biopsy. The treatment course comprised R-CHOP chemotherapy. She had undergone a living-donor kidney transplantation 22 years ago. During the fifth cycle of R-CHOP, a pharmacist observed exertional dyspnea and edema of the left lower extremity. Transthoracic echocardiography revealed a decrease in global longitudinal strain; however, elevated D-dimer levels were noted. Additionally, the edema was unilateral, leading the pharmacist to suspect cancer-associated thrombosis as a possible cause of the lower extremity edema. The patient had been receiving daprodustat to treat renal anemia. However, because daprodustat is known to pose some risk to patients with thromboembolic disease, the pharmacist provided the attending physicians with information relevant to the discontinuation of daprodustat. Subsequently, the patient was diagnosed with left lower-extremity deep vein thrombosis, and daprodustat was discontinued.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"579-582"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Association Between Tertiary Lymphoid Structures and Intratumoral Microbiota in Lung Cancer]. 肺癌三级淋巴结构与肿瘤内微生物群的关系

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Sho Inomata, Kazuyuki Hamada, Yuki Ozaki, Satoshi Muto, Yoshiki Suzuki, Yoshiyuki Maruya, Hikaru Yamaguchi, Hayato Mine, Masayuki Watanabe, Mitsuo Fukuhara, Naoyuki Okabe, Hiroyuki Suzuki

引用次数: 0

[Prostate-Preserving Curative Surgery for Isolated Peritoneal Recurrence with Seminal Vesicle Invasion Following Sigmoid Colon Cancer Resection-A Case Report]. [乙状结肠切除术后孤立腹膜复发伴精囊侵犯的保前列腺根治性手术1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Fuka Fujimoto, Shigeyuki Kosaka, Naoi Sato, Haruka Shigemori, Haruka Kirihara, Ryo Nakajima, Shinnosuke Harata, Kawori Watanabe, Tomoya Shamoto, Kazuyoshi Shiga, Tatsuya Tanaka, Yoichi Matsuo, Shuji Takiguchi

{"title":"[Prostate-Preserving Curative Surgery for Isolated Peritoneal Recurrence with Seminal Vesicle Invasion Following Sigmoid Colon Cancer Resection-A Case Report].","authors":"Fuka Fujimoto, Shigeyuki Kosaka, Naoi Sato, Haruka Shigemori, Haruka Kirihara, Ryo Nakajima, Shinnosuke Harata, Kawori Watanabe, Tomoya Shamoto, Kazuyoshi Shiga, Tatsuya Tanaka, Yoichi Matsuo, Shuji Takiguchi","doi":"","DOIUrl":"","url":null,"abstract":"A 61-year-old man presented with bowel obstruction caused by sigmoid colon cancer that was detected during screening. After colonic stenting, laparoscopic sigmoidectomy was performed (pT3N0M0, Stage Ⅱa). Follow-up CT performed 2 years later revealed a nodular lesion anterior to the rectum. MRI and PET-CT confirmed peritoneal recurrence invading the rectum and bilateral seminal vesicles. Neoadjuvant chemotherapy comprising 5 courses of mFOLFOX6 plus bevacizumab reduced the tumor size from 19 × 12 mm to 11 × 7 mm. Although total pelvic exenteration was initially considered, tumor shrinkage ultimately enabled prostate preservation. Robot-assisted laparoscopic low anterior resection with bilateral seminal vesicle resection and a diverting stoma was performed. The patient's postoperative course was uneventful, allowing discharge on postoperative day 10. Pathological examination confirmed negative margins, indicating curative resection. This case suggests that chemotherapy-induced tumor shrinkage may facilitate organ-preserving surgery in patients with advanced recurrent colorectal cancer.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"595-597"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Pembrolizumab-Associated Fulminant Type One Diabetes Mellitus during Neoadjuvant Chemotherapy for Early-Stage Breast Cancer]. [早期乳腺癌新辅助化疗期间伴有派姆单抗相关暴发性1型糖尿病1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Rumi Amano, Hirohito Seki, Kazuki Yasuda, Shoko Yao, Ai Tsuchiya, Kaisuke Miyamoto, Yoshiharu Ishizaka, Kaishi Satomi, Yoshika Wada, Shigeru Imoto

{"title":"[A Case of Pembrolizumab-Associated Fulminant Type One Diabetes Mellitus during Neoadjuvant Chemotherapy for Early-Stage Breast Cancer].","authors":"Rumi Amano, Hirohito Seki, Kazuki Yasuda, Shoko Yao, Ai Tsuchiya, Kaisuke Miyamoto, Yoshiharu Ishizaka, Kaishi Satomi, Yoshika Wada, Shigeru Imoto","doi":"","DOIUrl":"","url":null,"abstract":"A woman in her 50s was diagnosed with Stage ⅡA triple-negative breast cancer (TNBC) and neoadjuvant chemotherapy with pembrolizumab, carboplatin, and paclitaxel was initiated. On day 125 of treatment, the patient presented to the emergency department with fever and impaired mobility. After a thorough examination, she was diagnosed with fulminant type 1 diabetes mellitus (T1DM) due to an immune-related adverse event (irAE). Prompt initiation of fluid resuscitation and insulin therapy led to symptom resolution. The patient was discharged on day 17 of hospitalization. One month later, adjuvant doxorubicin and cyclophosphamide (AC) therapy was initiated and completed for 4 courses. Subsequently, the patient achieved a clinical complete response (cCR) following neoadjuvant therapy, and subsequently underwent total mastectomy and sentinel lymph node biopsy of the left breast. The final pathological examination revealed a pathological complete response (pCR; ypT0/ypN0). Pembrolizumab was not administered postoperatively. One year after surgery, no evidence of recurrence was observed. Fulminant T1DM is a rare irAE with an incidence of < 0.1%. However, this condition rapidly progresses to diabetic ketoacidosis. When pembrolizumab is administered, early detection through regularly monitoring the patient's symptoms and blood glucose should be required.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"587-591"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Utility of Imaging Mass Cytometry in Spatial Analysis of Non-Small Cell Lung Cancer]. [成像细胞术在非小细胞肺癌空间分析中的应用]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Kazuyuki Hamada

{"title":"[Utility of Imaging Mass Cytometry in Spatial Analysis of Non-Small Cell Lung Cancer].","authors":"Kazuyuki Hamada","doi":"","DOIUrl":"","url":null,"abstract":"Immune checkpoint inhibitors have improved substantially clinical outcomes in patients with non-small cell lung cancer (NSCLC). However, considerable variability in therapeutic response persists even among tumors with the same histologic subtype or PD-L1 expression status. Recent studies have demonstrated that this heterogeneity is closely associated with the spatial architecture of the tumor microenvironment, including the localization and interactions of tumor cells, T cells, dendritic cells, macrophages, and fibroblasts. Imaging mass cytometry (IMC) combines metal isotope-labeled antibo dies, laser ablation, and time-of-flight mass spectrometry. This enables simultaneous analysis of multiple proteins in formalin-fixed paraffin-embedded tissue sections at single-cell resolution. Critically, spatial information is preserved throughout the process. By integrating artificial intelligence-driven image analysis, IMC enables the evaluation of cellular density and phenotype. It also enables the quantitative analysis of intercellular distance and cellular proximity. In NSCLC, intratumoral infiltration of CD8-positive T cells, spatial distribution of myeloid cells, maturation of tertiary lymphoid structures, and stromal barrier formation have all been associated with prognosis and response to immunotherapy. Furthermore, integration with artificial intelligence-based digital pathology has enabled the identification of complex spatial patterns that are difficult to detect using conventional histopathologic assessment alone. This review summarizes the principles and analytical concepts of IMC and discusses recent advances in spatial analysis in NSCLC, as well as its potential clinical applications.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"550-553"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Stage Ⅳ Lung Adenocarcinoma with Bilateral Breast Metastases Mimicking Inflammatory Breast Cancer]. [Ⅳ期肺腺癌合并双侧乳腺转移模拟炎性乳腺癌1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Masami Yako, Goro Yoshimura, Emi Date, Norishige Iizuka, Mitsuhiko Iwamoto, Masanobu Uchiyama, Junichi Matsumoto, Yuta Nakashima, Ayaka Shibata, Hideki Kakimoto, Takafumi Nakano, Masaya Adachi, Marie Yoshioka, Risako Fujikawa, Katsunori Iwasaki, Koichi Matsuo

{"title":"[A Case of Stage Ⅳ Lung Adenocarcinoma with Bilateral Breast Metastases Mimicking Inflammatory Breast Cancer].","authors":"Masami Yako, Goro Yoshimura, Emi Date, Norishige Iizuka, Mitsuhiko Iwamoto, Masanobu Uchiyama, Junichi Matsumoto, Yuta Nakashima, Ayaka Shibata, Hideki Kakimoto, Takafumi Nakano, Masaya Adachi, Marie Yoshioka, Risako Fujikawa, Katsunori Iwasaki, Koichi Matsuo","doi":"","DOIUrl":"","url":null,"abstract":"Breast metastases from primary lung cancers with inflammatory breast cancer (IBC)-like features are rare. Here, we report a patient with bilateral breast metastases from an advanced lung adenocarcinoma that mimicked IBC. A 67-year-old woman was diagnosed with right middle lobe lung adenocarcinoma with pleural and peritoneal dissemination (cT2aN2M1c, cStage ⅣB) and received systemic therapy. Twenty-nine months later, skin erythema and edema appeared in both breasts, suggesting bilateral IBC. Core needle biopsies of both breasts revealed atypical carcinomas without intraductal or lobular in situ components. Immunohistochemistry showed thyroid transcription factor-1 and Napsin A positivity and GATA3 negativity, supporting the diagnosis of metastatic lung adenocarcinoma of the breasts. Comprehensive genomic profiling of the breast specimen revealed an EGFR exon 19 deletion, and osimertinib achieved disease control within 1 year. This report highlights a diagnostic pitfall in which lung adenocarcinoma metastasis to the breast mimics IBC and underscores the importance of biopsy, an appropriate immunohistochemical panel, and molecular testing to establish a correct diagnosis and guide optimal systemic therapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"575-578"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer]. [预防米诺环素治疗转移性结直肠癌抗表皮生长因子受体抗体诱发皮肤相关不良事件的最佳用药时间]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Toshinori Yanagawa, Kozo Kataoka, Noriko Yamashita, Tomoko Demachi, Ryota Tanaka, Takeshi Nakamura, Kazuma Ito, Kei Kimura, Masataka Ikeda, Kuniyoshi Tanaka

{"title":"[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer].","authors":"Toshinori Yanagawa, Kozo Kataoka, Noriko Yamashita, Tomoko Demachi, Ryota Tanaka, Takeshi Nakamura, Kazuma Ito, Kei Kimura, Masataka Ikeda, Kuniyoshi Tanaka","doi":"","DOIUrl":"","url":null,"abstract":"Prophylactic administration of systemic antibiotics is widely used to mitigate skin-related adverse events (AEs) during anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC). However, the optimal duration of prophylaxis remains unclear, and prolonged use may increase risks such as hepatotoxicity and reduced efficacy. In this single-center retrospective study, mCRC patients receiving anti-EGFR mAbs and prophylactic minocycline as part of a standardized outpatient skin care program were analyzed. Patients were classified into 2 groups based on minocycline duration: 8 weeks or >8 weeks. The primary endpoint was the incidence of Grade ≥2 skin-related AEs at weeks 8 and 12. Secondary endpoints included specific AE types, liver dysfunction, and risk factor analysis using multivariate logistic and Cox regression models. Seventy-three patients were included (8-week group: n = 24; >8-week group: n = 49). At week 12, the incidence of Grade ≥2 skin-related AEs was significantly lower in the 8-week group (54.2% vs 81.6%, p = 0.013), particularly for paronychia (16.7% vs 42.9%, p = 0.027). The incidence of liver dysfunction was also lower (16.7% vs 40.8%, p = 0.039). Logistic regression identified younger age and prolonged minocycline use as independent risk factors at week 12, while Cox regression showed age ≥65 years increased risk over the treatment period. Limiting prophylactic minocycline administration to 8 weeks may reduce skin-related AEs and hepatotoxicity. Patient age and treatment duration should be considered when optimizing supportive care protocols for anti-EGFR mAbs therapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"569-573"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149115838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer]. [预防米诺环素治疗转移性结直肠癌中抗egfr抗体引起的皮肤相关不良事件的最佳用药时间]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2026-09-01

Toshinori Yanagawa, Kozo Kataoka, Noriko Yamashita, Tomoko Demachi, Ryota Tanaka, Takeshi Nakamura, Kazuma Ito, Kei Kimura, Masataka Ikeda, Kuniyoshi Tanaka

{"title":"[Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer].","authors":"Toshinori Yanagawa, Kozo Kataoka, Noriko Yamashita, Tomoko Demachi, Ryota Tanaka, Takeshi Nakamura, Kazuma Ito, Kei Kimura, Masataka Ikeda, Kuniyoshi Tanaka","doi":"","DOIUrl":"","url":null,"abstract":"Prophylactic administration of systemic antibiotics is widely used to mitigate skin-related adverse events (AEs) during anti-EGFR monoclonal antibody (mAb) therapy for metastatic colorectal cancer (mCRC). However, the optimal duration of prophylaxis remains unclear, and prolonged use may increase risks such as hepatotoxicity and reduced efficacy. In this single-center retrospective study, mCRC patients receiving anti-EGFR mAbs and prophylactic minocycline as part of a standardized outpatient skin care program were analyzed. Patients were classified into 2 groups based on minocycline duration: 8 weeks or >8 weeks. The primary endpoint was the incidence of Grade ≥2 skin-related AEs at weeks 8 and 12. Secondary endpoints included specific AE types, liver dysfunction, and risk factor analysis using multivariate logistic and Cox regression models. Seventy-three patients were included (8-week group: n = 24; >8-week group: n = 49). At week 12, the incidence of Grade ≥2 skin-related AEs was significantly lower in the 8-week group (54.2% vs 81.6%, p = 0.013), particularly for paronychia (16.7% vs 42.9%, p = 0.027). The incidence of liver dysfunction was also lower (16.7% vs 40.8%, p = 0.039). Logistic regression identified younger age and prolonged minocycline use as independent risk factors at week 12, while Cox regression showed age ≥65 years increased risk over the treatment period. Limiting prophylactic minocycline administration to 8 weeks may reduce skin-related AEs and hepatotoxicity. Patient age and treatment duration should be considered when optimizing supportive care protocols for anti-EGFR mAbs therapy.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"53 9","pages":"569-573"},"PeriodicalIF":0.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148983736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0